Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22736596 | 0.77 | SIGMAR1 (0.44) | JAK2NPSR1ALDH1A1TSHRHTT | |
| SCHEMBL14494879 | 0.77 | CHRM2 (0.46) | JAK2NPSR1ALDH1A1TSHRNOTUM | |
| SCHEMBL17813471 | 0.76 | EGFR (0.35) | JAK2NOTUM | |
| SCHEMBL16663591 | 0.75 | EGFR (0.35) | JAK2NOTUM | |
| SCHEMBL26618585 | 0.75 | ALDH1A1 (0.42) | ALDH1A1NOTUM | |
| SCHEMBL255037 | 0.72 | NOTUM (0.50) | NPSR1ALDH1A1TSHRNOTUMHTT | |
| SCHEMBL27305307 | 0.72 | SCN10A (0.34) | JAK2NOTUM | |
| SCHEMBL24651359 | 0.71 | CHRM2 (0.46) | JAK2NPSR1ALDH1A1TSHRNOTUM | |
| SCHEMBL25061880 | 0.71 | CHRM2 (0.46) | JAK2NPSR1ALDH1A1TSHRNOTUM | |
| SCHEMBL14507337 | 0.70 | ALDH1A1 (0.36) | JAK2NPSR1ALDH1A1TSHRNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | JAK2 3833/4885NPSR1 561/4885ALDH1A1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.